A Philadelphia biotechnology company has tentatively agreed to pay $2.75 million to resolve a lawsuit brought by its shareholders, who allege the company made "material misrepresentations and omissions" regarding the status of a new drug application for its lead new drug candidate. The class action lawsuit was filed against Hemispherx Biopharma , which has spent more than three decades developing Ampligen for a variety of possible uses.